Cargando…

Lower Cerebrospinal Fluid Amyloid-β(42) Predicts Sooner Time to Antipsychotic Use in Alzheimer’s Disease

BACKGROUND: Cerebrospinal fluid (CSF) biomarkers of amyloid-β(42) (Aβ(42)) and phosphorylated-tau help clinicians accurately diagnose Alzheimer’s disease (AD). Whether biomarkers help prognosticate behavioral and psychological symptoms of dementia (BPSD) is unclear. OBJECTIVE: Determine whether CSF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cahan, Joshua G., Vassar, Robert, Bonakdarpour, Borna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357113/ https://www.ncbi.nlm.nih.gov/pubmed/37483323 http://dx.doi.org/10.3233/ADR-220064

Ejemplares similares

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2019)

β-Amyloid (1–42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease
por: Kaiser, Elmar, et al.
Publicado: (2011)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Cerebrospinal Fluid β-Amyloid(1–42) Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis
por: Mo, Jin-A, et al.
Publicado: (2015)

Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis
por: Stroffolini, Giacomo, et al.
Publicado: (2021)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ(42,) in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents
por: Kounnas, Maria Z., et al.
Publicado: (2016)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid
por: Frankel, Rebecca, et al.
Publicado: (2019)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease
por: Dorey, Aline, et al.
Publicado: (2015)

Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients
por: Kim, Hyun Jae, et al.
Publicado: (2019)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

The Cerebrospinal Fluid Aβ(1–42)/Aβ(1–40) Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
por: Jia, Longfei, et al.
Publicado: (2021)

Aβ42 as a Biomarker of Alzheimer’s Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?
por: Boschi, Silvia, et al.
Publicado: (2022)

Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
por: Introna, Alessandro, et al.
Publicado: (2021)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

The Relationship between Different Assays for Detection and Quantification of Amyloid Beta 42 in Human Cerebrospinal Fluid
por: Ellis, Teresa A., et al.
Publicado: (2012)

Cerebrospinal Fluid Amyloid β(1-42), Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease
por: Kang, Ju-Hee
Publicado: (2016)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis
por: Sturchio, Andrea, et al.
Publicado: (2021)

Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Maftei, Madalina, et al.
Publicado: (2013)

Timing of therapies for Down syndrome: the sooner, the better
por: Stagni, Fiorenza, et al.
Publicado: (2015)

Timing of cardioversion in atrial fibrillation: the sooner the better?
por: Capranzano, Piera, et al.
Publicado: (2020)

Shear-Induced Amyloid Aggregation in the Brain: V. Are Alzheimer’s and Other Amyloid Diseases Initiated in the Lower Brain and Brainstem by Cerebrospinal Fluid Flow Stresses?
por: Trumbore, Conrad N.
Publicado: (2021)

The second shot to walled‐off necrosis: The sooner the better versus sooner or later
por: Sato, Tatsuya, et al.
Publicado: (2022)

Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele
por: Padayachee, E.R., et al.
Publicado: (2016)

Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic
por: Müller, Ebba Gløersen, et al.
Publicado: (2019)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
por: Turk, Katherine W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dujriglb0u4qhq959v5m8a69ga